Recombinant Human Glypican 3 Protein Summary
Product Specifications
Gln25-His559 with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
2119-GP
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
Reconstitution | Reconstitute at 10 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
2119-GP/CF
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
![Graph showing bioactivity of human Glypican-3 protein Graph showing bioactivity of human Glypican-3 protein](https://aeroglobalimagesuat.blob.core.windows.net/images/datasheets/protein/2119-gp_recombinant-human-glypican-3-protein-bioactivity-1412202082934.jpg)
Recombinant human Glypican 3 (2119-GP) binds recombinant human FGF basic 146 in a functional ELISA. The concentration of recombinant human FGF basic 146 that produces 50% of the optimal binding response is 0.6-3 ng/mL.
Reconstitution Calculator
Background: Glypican 3
Glypicans (GPC) are a family of heparan sulfate proteoglycans that are attached to the cell surface by a glycosylphosphatidylinositol (GPI) anchor. Six members of this family have been identified in mammals (GPC1-GPC6). All glypican core proteins contain an N-terminal signal peptide, a large globular cysteine-rich domain (CRD) with 14 invariant cysteine residues, a stalk-like region containing the heparan sulfate attachment sites, and a C-terminal GPI attachment site. While glypican proteins do not share strong amino acid sequence identity (they range from 17-63%), the conserved cysteine residues in their CRDs suggests similarity in their
three‑dimensional structure (1, 2).
Mutations in GPC3 cause a rare disorder in humans, Simpson-Golabi-Behmel Syndrome, which is characterized by pre and postnatal overgrowth of multiple tissues and organs and an increased risk for developing embryonic tumors (3). These features are also present in the mouse knock-out of GPC3 indicating that GPC3 regulates cell survival and inhibits cell proliferation during development (4). Glypican 3 has been implicated in regulating many different signaling pathways including: IGF, FGF, BMP and Wnt. An endoproteolytic processing of GPC3 by proprotein convertases is required for the modulation of Wnt signaling (5). Direct interaction with FGF-basic has been observed and is mediated by the heparan sulfate chains (6).
- Filmus, J. and S.B. Selleck (2001) J. Clinical Invest. 108:497.
- De Cat, B and G. David (2001) Seminars in Cell & Dev. Biol. 12:117.
- Pilia, G. et al. (1996) Nat. Genet. 12: 241.
- Cano-Gauci, D.F. et al. (1999) J. Cell Biol. 146: 255.
- De Cat, B. et al. (2003) J. Cell Biol. 163:625.
- Song, H.H. et al. (1997) J. Biol. Chem. 272:7574.
Citations for Recombinant Human Glypican 3 Protein
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
7
Citations: Showing 1 - 7
Filter your results:
Filter by:
-
BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity
Authors: TL Hickman, E Choi, KR Whiteman, S Muralidhar, T Pai, T Johnson, A Parikh, T Friedman, M Gilbert, B Shen, L Barron, KE McGinness, SA Ettenberg, GT Motz, GJ Weiss, A Jensen-Smi
PLoS ONE, 2022-05-04;17(5):e0266980.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells
Authors: T Ueda, A Kumagai, S Iriguchi, Y Yasui, T Miyasaka, K Nakagoshi, K Nakane, K Saito, M Takahashi, A Sasaki, S Yoshida, N Takasu, H Seno, Y Uemura, K Tamada, T Nakatsura, S Kaneko
Cancer Sci., 2020-03-31;111(5):1478-1490.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo -
Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery
Authors: M Miura, N Fujinami, Y Shimizu, S Mizuno, K Saito, T Suzuki, M Konishi, S Takahashi, N Gotohda, K Suto, T Yoshida, T Nakatsura
Oncol Lett, 2020-02-05;19(4):2657-2666.
Species: Human
Sample Types: Plasma
Applications: ELISA Development -
Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate
Sci Rep, 2016-05-17;6(0):26245.
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA (Standard) -
Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Clin. Cancer Res., 2012-05-10;18(13):3686-96.
Applications: ELISA (Standard) -
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Authors: Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y
Clin. Cancer Res., 2006-05-01;12(9):2689-97.
Applications: ELISA (Standard) -
Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
Authors: Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, Komori H, Fukuma D, Baba H, Nishimura Y
Cancer Res., 2006-02-15;66(4):2414-22.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human Glypican 3 Protein
There are currently no reviews for this product. Be the first to review Recombinant Human Glypican 3 Protein and earn rewards!
Have you used Recombinant Human Glypican 3 Protein?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image